Display Settings:

Format

Send to:

Choose Destination
    Eur Neurol. 2010;64(5):258-64. Epub 2010 Oct 15.

    Intravenous tissue plasminogen activator thrombolysis in patients without major arterial occlusion seems to be safe and effective.

    Source

    Department of Stroke Medicine, Kawasaki Medical School, Okayama, Japan. kimurak@med.kawasaki-m.ac.jp

    Abstract

    BACKGROUND:

    It is not clear whether tissue plasminogen activator (t-PA) thrombolysis in patients without major arterial occlusion is effective or safe.

    METHODS:

    Consecutive anterior circulation stroke patients treated with t-PA within 3 h of onset were studied. The patients were divided into three groups according to magnetic resonance angiography findings before t-PA infusion: ICA group, ICA occlusion; MCA group, M1 and M2 occlusion, and no occlusion group. Clinical characteristics, the presence of hemorrhagic transformation on T₂* at 24 h after t-PA thrombolysis, and outcome at 3 months were compared among the three groups.

    RESULTS:

    112 patients were enrolled. The no occlusion group had 21 (18.8%) patients, the ICA group had 29 (25.9%), and the MCA group had 62 (55.4%). The frequency of hemorrhagic transformation was only 4.8% in the no occlusion group (31.0% for the ICA group, and 48.4% for the MCA group, p = 0.0012). At 3 months after t-PA therapy, 61.5% of the no occlusion group had a favorable outcome (modified Rankin score 0-1), which was the highest among the three groups (15.0% for the ICA group, and 41.5% for the MCA group, p = 0.0203).

    CONCLUSION:

    Intravenous t-PA therapy in acute stroke patients without major artery occlusion seems to be safe and effective.

    Copyright © 2010 S. Karger AG, Basel.

    PMID:
    20948218
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for S. Karger AG, Basel, Switzerland

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk